Merck KGaA is joining the global migration to the greater Boston biotech hub.
The German biopharma is building a new life sciences campus in Burlington, styling the 280,000-square-foot facility as a “customer collaboration laboratory and training center.” And it’s one of 9 collaboration complexes planned for Brazil, China, France, India, Singapore and South Korea.
The company is spending $115 million on the project, with room left for a 70,000-square-foot addition, if it needs it. Merck’s subsidiary, MilliporeSigma, will relocate its 850 full-time Billerica-based employees when construction is complete in the second half of 2017.
Like a long list of biopharma companies, Merck KGaA already has a significant R&D presence in the greater Cambridge/Boston area. And like others, it’s moving more of its R&D work into an area that has a rep as one of the world’s most important biotech hubs, with MIT and Harvard and other academic institutions acting as a brainstorming arm for new drug development.
That profile has persuaded Pfizer, Merck, Bristol-Myers, Shire and many others to concentrate in the area, as a torrent of investor cash backs a wave of local biotech startups. And more are likely to jump in in coming years.
Merck KGaA has had to survive a tumultuous decade, marked by a series of setbacks in the clinic. Four years ago it opted to close its Geneva operations, 5 years after it got the campus in its $13 billion Serono buyout. That major shakeup cost hundreds of jobs, with hundreds more shifted to its headquarters in Darmstadt. And throughout, Merck KGaA has yet to develop a single major new drug. On the other hand, Pfizer paid a record $850 million up front to partner on a checkpoint inhibitor, which may rank as the fifth entry in that field.
The best place to read Endpoints News? In your inbox.
Comprehensive daily news report for those who discover, develop, and market drugs. Join 44,900+ biopharma pros who read Endpoints News by email every day.Free Subscription